Pharmacyte Biotech Inc (OTCMKTS:PMCB) reported that its COO Dr. Gerald W. Crabtree, Ph.D., and CEO, Mr. Kenneth L. Waggoner, JD have been featured in the September edition of PharmaVOICE Magazine.
Waggoner, the CEO said that they are relying greatly on the advice of the three world known physicians in oncology in developing of upcoming clinical trial in people suffering with advanced pancreatic cancer and in an another study the management is in the planning process. Working collaboratively, the input of these three physicians has enable company to formulate a strategy to deal with an unmet medical need for this appalling disease and has facilitated company avoid drawbacks that otherwise might have recorded.
Stellar Biotechnologies Inc (OTCMKTS:SBOTF) Updates On Reverse Stock Split Process
Stellar Biotechnologies Inc (OTCMKTS:SBOTF) disclosed that as per the regulatory approval, they plan to complete the consolidation of company’s issued and outstanding “Shares.” They will opt for a 1-10 reverse stock split, the proposal of which was approved on August 26, 2015. Stellar Biotechnologies desires to list up on the NASDAQ Capital Market in coming period.
The company has submitted an application to get its shares listed on NASDAQ and the quantitative guideline can be met only after the planned Reverse Stock Split.
Biostem US Corp (OTCMKTS:HAIR) Halts Business Operations
Biostem US Corp (OTCMKTS:HAIR) had suspended of all of its business operations due to ongoing financial problems. The company terminated its employee, halted recruitment of medical partners, closed its website and stopped marketing initiatives.
The company last reported its financial numbers in 2013 and since then has not filed any financial report with the U.S. SEC. As of May 2013, the assets were $3,636 while total liabilities stood at $917,298. Biostem still has to make payments to its professional advisors in lieu of their services.
In last trading session, the stock price of Pharmacyte gained more than 1% to close the trading session at $0.0974.
